David Michelson, MD

Chief Medical Officer

David Michelson is the chief medical officer of Proclara. He joins Proclara after more than a decade at Merck Research Laboratories, where he oversaw clinical development of both early and late phase programs, including MK-8931, Merck’s BACE inhibitor for the treatment of Alzheimer’s disease, and led the successful NDA submissions of tafluprost, suvorexant, and sugammadex. Prior to joining Merck, he held multiple roles at Eli Lilly and Company, including serving as a senior medical director for the atomoxetine development group (Strattera®, a compound for ADHD), and led its clinical development and regulatory submissions in the US and globally.  He later became the executive medical director of Eli Lilly’s Neuroscience Therapeutic Area, where he oversaw the company’s early phase neuroscience clinical development program, including compounds with psychiatric, neurologic and pain/migraine indications. Before joining Eli Lilly, Dr. Michelson served as a member of the clinical neuroendocrinology branch of the National Institute of Mental Health and as a faculty member at Yale University. Dr. Michelson received his B.A. in English from Wesleyan University. Following a period serving as a teacher in the Peace Corps, he received his M.D. from the Albert Einstein College of Medicine in New York. He completed his internship and residency in psychiatry at Yale University, where he was also chief resident.